Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA, Hwu CM, Jammah AA, Arteaga-Díaz JM, Djaballah K, Pilorget V, Alvarez A, Vera C, Vikulova O. Malik RA, et al. Among authors: alvarez a. Diabetes Obes Metab. 2024 Jul;26(7):2811-2819. doi: 10.1111/dom.15599. Epub 2024 Apr 18. Diabetes Obes Metab. 2024. PMID: 38637981
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
McCrimmon RJ, Home P, Cheng A, Giorgino F, Fonseca V, Souhami E, Alvarez A, Picard P, Rosenstock J. McCrimmon RJ, et al. Among authors: alvarez a. Diabetes Obes Metab. 2022 Dec;24(12):2391-2399. doi: 10.1111/dom.14825. Epub 2022 Aug 23. Diabetes Obes Metab. 2022. PMID: 36054624 Free PMC article.
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
McCrimmon RJ, Al Sifri S, Emral R, Mohan V, Sauque-Reyna L, Trescolí C, Lalic N, Alvarez A, Demil N, Coudert M, Shaunik A, Bonnemaire M, Rosenstock J; SoliMix Trial investigators. McCrimmon RJ, et al. Among authors: alvarez a. Diabetes Obes Metab. 2021 Jun;23(6):1221-1231. doi: 10.1111/dom.14354. Epub 2021 Apr 29. Diabetes Obes Metab. 2021. PMID: 33606908 Clinical Trial.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Rosenstock J, et al. Among authors: alvarez a. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. Diabetes Care. 2021. PMID: 34183429 Free PMC article.
[Microorganisms isolated from blood cultures and resistance profile in children with cancer and high-risk febrile neutropenia. Red PINDA, Chile, 2016-2021].
Valenzuela R, Riquelme C, de la Maza V, Álvarez AM, Contardo V, Ducasse K, Payá E, Claverie X, Venegas M, Santolaya ME. Valenzuela R, et al. Among authors: alvarez am. Andes Pediatr. 2024 Apr;95(2):143-150. doi: 10.32641/andespediatr.v95i2.5012. Epub 2024 Apr 29. Andes Pediatr. 2024. PMID: 38801361 Free article. Spanish.
2,215 results